Glial cell line-derived neurotrophic factor receptor complex (GDNF receptor complex)

The Glial cell line-derived neurotrophic factor (GDNF) receptor complex is a multi-subunit signaling assembly essential for the development and maintenance of various neuronal populations, particularly midbrain dopaminergic neurons and spinal cord motor neurons (Bespalov & Saarma, 2007). The complex typically consists of a ligand-binding co-receptor, GDNF family receptor alpha-1 (GFRα1), and a signaling transmembrane receptor tyrosine kinase, Rearranged during Transfection (RET) (Jing et al., 1996). Upon GDNF binding to GFRα1, the complex promotes RET homodimerization and autophosphorylation, triggering downstream pathways such as MAPK/ERK, PI3K/Akt, and PLCγ (Airaksinen & Saarma, 2002). Beyond the nervous system, this receptor complex plays a critical role in kidney morphogenesis and spermatogenesis (Sidorova et al., 2010). Therapeutically, the GDNF receptor complex is a primary focus for treating neurodegenerative disorders like Parkinson's disease and amyotrophic lateral sclerosis (ALS) through the use of recombinant GDNF or small-molecule agonists (Allen et al., 2013). Conversely, dysregulation or oncogenic mutations in the RET component are implicated in medullary thyroid carcinoma and non-small cell lung cancer, making it a target for selective kinase inhibitors like selpercatinib (Subbiah et al., 2020). Significant challenges in targeting this complex include the requirement for invasive delivery to bypass the blood-brain barrier and the potential for off-target effects due to its broad physiological roles (Bartus et al., 2013).

Other names

GFRα1/RET complexRET/GFRα1 receptor complexGDNF family receptor complexGDNFR-alpha/RET complex

Agonism of the RET receptor tyrosine kinase to promote neuronal survival and regeneration; Inhibition of the RET receptor tyrosine kinase to treat RET-driven malignancies; Activation of downstream MAPK/ERK and PI3K/Akt signaling pathways.